ARTICLE | Clinical News
MVA-Muc1-IL2 vaccine: TRGNY started a European Phase II trial of MVA-Muc1-IL2 given as a single agent or in combination with Navelbine/cisplatin chemotherapy in
January 28, 2002 8:00 AM UTC
Transgene S.A. (NM:Transgene; TRGNY), Strasbourg, France Product: MVA-Muc1-IL2 vaccine Business: Cancer Therapeutic category: Gene therapy Target: Immune system Description: Attenuated MVA vaccinia vi...